EMEA-002665-PIP02-20

Key facts

Active substance
Loncastuximab tesirine
Therapeutic area
Oncology
Decision number
P/0400/2021
PIP number
EMEA-002665-PIP02-20
Pharmaceutical form(s)
Powder for concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of mature B-cell neoplasms
Route(s) of administration
Intravenous use
Contact for public enquiries
Swedish Oprhan Biovitrum AB (publ)

Email: info@sobi.com
Tel. +46 8 697 20 00

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating